Minoo Ahmadinejad Explores Emicizumab
Minoo Ahmadinejad, Laboratory Director at Iranian Blood Transfusion Organization, shared on LinkedIn:
”Advances in hemophilia management had introduced novel therapies that challenged traditional approaches to laboratory monitoring.
Yesterday, I presented to medical doctors and specialists in hemato‑oncology on Emicizumab—a bispecific monoclonal antibody—and its impact on interpreting conventional coagulation assays.
Because standard tests such as aPTT and one-stage factor VIII activity appeared normalized.
The methods for measuring Emicizumab concentration needs modified specialized assays and measurements of FVIII activity or it’s inhibitor in the patient’s on Emicizumab treatment required chromogenic factor VIII tests with bovine reagents, for accurate assessment.
Through this discussion, I highlighted the key laboratory considerations, potential pitfalls, and strategies clinicians needed to adopt to ensure safe and effective patient care under this innovative treatment.”

Stay updated with Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation